Pfizer Arthritis Pill Approved by FDA for Sale as Xeljanz
This article is for subscribers only.
Pfizer Inc.’s experimental rheumatoid arthritis pill won U.S. regulatory approval and will compete directly with Abbott Laboratories’ top-selling injection Humira.
The Food and Drug Administration cleared Pfizer’s treatment, tofacitinib, to be sold as Xeljanz, for adults with moderate to severe rheumatoid arthritis who don’t respond well to other drugs, the agency said today in a statement.